Sanofi diabetes drug awaits imminent EU green light

February 26, 2015 3:50 PM

13 0

LONDON (Reuters) - Sanofi's new Toujeo diabetes drug is on track to receive a potential green light from European regulators this week, building on a U.S. regulatory approval awarded on Wednesday.

Toujeo is a more potent follow-up to the French drugmaker's top-selling Lantus insulin product, which accounts for a fifth of group sales, and the new drug is pivotal to Sanofi's diabetes business as Lantus faces loss of patent protection.

Read more

To category page